[ad_1] On June 26, 2018, Valeant (VRX) announced the conclusion of an exclusive co-promotion agreement with Lucemyra (lofexidine), the American Worldmeds. The first of its kind of treatment to help alleviate opioid …
Read More »Lucemyra: An Underrated Opportunity for Valeant – Valeant Pharmaceuticals International, Inc. (NYSE: VRX)
